This study aims to find out whether vitamin-C can perevent the excess DNA methylation associated with TET2 mutations

The effect of vitamin C on the gene methylation load in patients with TET2 mutations - vitamin C epigenome

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2018-000155-41-FI

Enrollment

Registered

2019-01-04

Start date

2019-01-10

Completion date

Unknown

Last updated

2025-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

germline TET-2 gene mutation

Interventions

Product Name: Vitamin-C Product Code: not applicable Pharmaceutical Form: Tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Age 18 or older 2) The person has been detected to have a germline TET 2 gene mutation (mutation carrier) , or belongs to same family (controls) 3) Written informed consent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 6 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 2

Exclusion criteria

Exclusion criteria: 1) Renolithiasis 2) Other drugs interacting with vitamin-C

Design outcomes

Primary

Measure	Time frame
Main Objective: To find out if vitamin C is able to prevent TET-2 mutation associated hypermetylation;Secondary Objective: not applicable;Primary end point(s): Stage of hypermetylation;Timepoint(s) of evaluation of this end point: One year	—

Secondary

Measure	Time frame
Secondary end point(s): Not applicable;Timepoint(s) of evaluation of this end point: Not applicable	—

Countries

Finland

Contacts

Public ContactStudy nurse

University of Helsinki

lauri.aaltonen@helsinki.fi

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026